Ultragenyx Pharmaceutical Inc. (RARE) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on January 10, 2022, by Ultragenyx Pharmaceutical Inc. The filing discloses preliminary unaudited fiscal year 2021 revenue figures for the products Crysvita (in Ultragenyx territories) and Dojolvi (global), as well as cash and investment positions at the end of fiscal year 2021. The company also provided 2022 revenue guidance for these products. Full year 2021 results are expected to be reported in February 2022.
Key Financial Metrics
The filing text references the announcement of specific financial data but does not contain the numerical values within the body of the 8-K itself. The specific figures for revenue, profit, cash flow, margins, debt, and liquidity are contained in the attached Press Release (Exhibit 99.1) and the investor presentation, which are not included in the provided text. Therefore, the filing text does not provide a clear value for these metrics.
Material Changes and Guidance
The company issued a press release and an investor presentation regarding preliminary 2021 results and 2022 guidance. The filing notes that Crysvita revenue includes collaboration revenue from the North American profit share territory (United States and Canada) and other regions such as Latin America and Turkey under an agreement with Kyowa Kirin Co., Ltd. No specific material changes versus prior periods or detailed guidance numbers are stated in the text of this report.
Risks and Contingencies
The filing includes standard disclaimers stating that the information in Item 2.02 and the attached exhibits shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor incorporated by reference in any filing under the Securities Act of 1933, except as expressly set forth by specific reference. No specific new risks or contingencies are detailed in the text of this report.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for the specific preliminary 2021 revenue numbers for Crysvita and Dojolvi.
- Verify the exact cash and investments balance at fiscal year-end 2021 from the attached press release.
- Confirm the specific 2022 revenue guidance ranges provided in the press release.
- Check the investor presentation posted on the company website for additional context on the J.P. Morgan Healthcare Conference.
- Monitor the upcoming February 2022 filing for the full audited fiscal year 2021 results.